A multi-centre, randomised, single-blind Phase I/IIa study to evaluate the safety, tolerability and efficacy of a single topical dose of allogeneic integrin α10β1-selected mesenchymal stem cells (XSTEM-VLU) in patients with difficult-to-heal venous leg ulcers

2024-518757-42-00 Protocol XIN-XSTEM-201 Phase I and Phase II (Integrated) - Other Ended

Start 28 Oct 2024 · End 11 Feb 2026 · Status Ended · 1 EU/EEA countries · 4 sites · Protocol XIN-XSTEM-201

Overview

Sponsor-declared trial summary

Phase Phase I and Phase II (Integrated) - Other
Status Ended
Participants planned 6
Countries 1
Sites 4

Difficult-to-heal venous leg ulcers

Key facts

Sponsor
Xintela AB
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Skin and Connective Tissue Diseases [C17]
Trial duration
28 Oct 2024 → 11 Feb 2026
Decision date (initial)
2024-10-28
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-518757-42-00
EudraCT number
2022-000492-39
ClinicalTrials.gov
NCT05549609

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Difficult-to-heal venous leg ulcers

VersionLevelCodeTermSystem organ class
21.1 LLT 10024946 Lower extremities ulcers of 10040785

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Xintela AB

Sponsor organisation
Xintela AB
Address
Medicon Village
City
Lund
Postcode
223 81
Country
Sweden

Scientific contact point

Organisation
Xintela AB
Contact name
Camilla Wennersten

Public contact point

Organisation
Xintela AB
Contact name
Camilla Wennersten

Locations

1 EU/EEA country · 4 investigational sites

By country

CountryMS statusPlanned subjectsSites
Sweden Ended 6 4
Rest of world 0

Investigational sites

Sweden

4 sites · Ended
Region Skane Skanes Universitetssjukhus
Clinical Trial Unit, Entregatan 7, 222 42, Lund
CTC Clinical Trial Consultants AB
CTC Clinical Trial Consultants AB, CTC Karolinska, Dag Hammarskjolds Vag 10b, Uppsala Domkyrkofors., Uppsala
Region Oestergoetland
Hand and Plastic Surgery, Universitetssjukhuset I, 58185, Linkoping
Sahlgrenska University Hospital-Vaestra Goetalandsregionen
Gothia Forum, Clinical Trial Center, Gröna Stråket 12, 41346 Gothenburg, Bla Straket 5, Goteborgs Annedal, Goteborg

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Sweden 2024-10-28 2026-02-11 2024-10-28 2025-10-01

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-10-15 Sweden Acceptable
2024-10-28
2024-10-28
2 SUBSTANTIAL MODIFICATION SM-1 2025-02-05 Sweden Acceptable
2025-04-07
2025-04-07
3 NON SUBSTANTIAL MODIFICATION NSM-1 2025-04-11 Sweden Acceptable
2025-04-07
2025-04-11